TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01775384

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrasorb
Description: from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00427700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: 100mg PO on days 5-9 of the menstrual cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: 100mg PO on days 5-9 of the menstrual cycle
Study: NCT04277312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage
Description: The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage
Description: The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nourish
Description: The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nourish
Description: The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
Study: NCT03580382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-3379 (ERBB3 antibody)
Description: 15mg/kg IV Q3W
Study: NCT02702050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation (LPG system; Cellu M6 Integral I)
Description: For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
Study: NCT05612282

Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
Study: NCT02702050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
Study: NCT00601744

Intervention type: BEHAVIORAL
Intervention: Audio-Taped Interview
Description: Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration.

Intervention type: BEHAVIORAL
Intervention: Audio-Taped Interview
Description: Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration.
Study: NCT03451240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corporate Athlete® Resilience
Description: The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work.
Study: NCT00601744

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 5-10 minute questionnaire to be completed after the interview.
Study: NCT03497026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Bronchoscopy Platform
Description: Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
Study: NCT02155764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octacalcium phosphate
Description: Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tricalcium phosphate
Description: Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
Study: NCT03986775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isomaltulose
Description: replacement of sucrose with low-glycemic isomaltulose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: conventional beverage with sucrose
Study: NCT00798655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day.
Study: NCT04317352

Intervention type: PROCEDURE
Intervention: MVR
Description: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
Study: NCT02765633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Study: NCT01679093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron: 4 mg intravenous administration afer the induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol
Description: droperidol: 1.25 mg intravenous administration after the induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexametasone: 4 mg intravenous administration after the induction of anesthesia.
Study: NCT00731263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Study: NCT02363270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV Push or or IV Drip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV Push or or IV Drip
Study: NCT00442013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
Study: NCT02156960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab treatment in osteoporotic patients
Description: To examine the effectiveness of denosumab in osteoporotic patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment in osteoporotic patients
Description: To examine the effectiveness of teriparatide in osteoporotic patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab and teriparatide treatment in osteoporotic patients
Description: To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
Study: NCT02025491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
Study: NCT01870219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine was given to 1mg/kg ıv bolus
Study: NCT02395497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal Antibody (Humanized Anti-CD52)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile Allotransplantation
Study: NCT04624035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Collamer Lens (ICL) in treatment of myopia in adults.
Description: ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.
Description: IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
Study: NCT03919864

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONTROL Group
Description: Participants will receive a generic printed list of hospital, community, and national supportive care resources.
Study: NCT04045977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapeutic support
Description: 8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic support
Description: 8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
Study: NCT00598208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection
Description: Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
Study: NCT02350842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: triple-site biventricular pacing with peri-operative echo guidance
Description: placement of the third lead by peri-operative echo guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard biventricular pacing
Description: standard biventricular pacing without optimization by echo guidance
Study: NCT04832048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercise
Description: The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercise
Description: The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No physical exercise
Description: No programmed physical exercise
Study: NCT03380520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Ferric carboxymaltose will be administered according to product specification dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV nacl 0.9%
Study: NCT04523610

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth phone calls
Description: The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth phone calls
Description: The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).

Intervention type: OTHER
Group type: OTHER
Intervention: Volunteer of TIP-OA Program
Description: Participant is a volunteer of the TIP-OA Program

Intervention type: OTHER
Group type: OTHER
Intervention: Stakeholder of TIP-OA Program
Description: Participant is a stakeholder of the TIP-OA Program
Study: NCT02323165

Intervention type: OTHER
Intervention: Molecular Detection of Bacteria in the Bloodstream
Description: Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
Study: NCT02006537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
Study: NCT02791087

Intervention type: OTHER
Intervention: Computed Tomography Angiography
Description: The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.

Intervention type: OTHER
Intervention: Computed Tomography Angiography
Description: The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
Study: NCT02438982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
Study: NCT00749502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).